

ROPES & GRAY  
ONE INTERNATIONAL PLACE  
BOSTON, MA 02110-2624  
PHONE: (617) 951-7000  
FAX: (617) 951-7050

OFFICIAL

**FAX TRANSMITTAL LETTER****FAX RECEIVED**Total Number of pages including this transmittal letter: 8

JAN 11 2001

NameFirm/CompanyFax NumberPhone Number**Examiner Pak****U.S. Patent Office****(703) 308-4242****GROUP 1600**

From: David P. Halstead

**IF YOU DO NOT RECEIVE ALL PAGES, PLEASE CALL IMMEDIATELY AT:****(617) 951-7000****IMPORTANT: PLEASE DELIVER THIS DOCUMENT IMMEDIATELY!**

---

**COMPLETE WHEN SUBMITTING TO FAX DEPARTMENT**

Date: January 10, 2002

Time: 2:31 PM

File Symbol: GPCI-P02-032

Personal ID Number: H28436

Submitted By: David P. Halstead

Phone: (617) 951-7000

---

Comments: **U.S. Application No.: 09/072,994**  
**Filing Date: May 5, 1998**  
**Group Art Unit: 1646**  
**Examiner: M. Pak**

THIS DOCUMENT IS INTENDED ONLY FOR THE USE OF THE PERSON TO WHOM IT IS ADDRESSED. IT MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL AND EXEMPT FROM DISCLOSURE UNDER APPLICABLE LAW. If you are not the intended recipient, any dissemination, distribution, copying or use of this document is strictly prohibited. If you have received this communication in error, please notify us by telephone (Collect: ) to arrange for the destruction or return of the original document to us.

#30/F (12)

8/10/02

1-15-02

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of:

Cottarel et al.

Serial No: 09/072,994

Filed: May 5, 1998

For: Cell-Cycle Regulatory Proteins  
from Human Pathogens, and Uses  
Related Thereto

Attorney Docket No. GPCI-P02-032

Art Unit: 1646

Examiner: M. Pak

**CERTIFICATE OF FACSIMILE**

I hereby certify that this correspondence is being transmitted by facsimile to the United States Patent and Trademark Office, Fax No. 703-308-4242, on the date indicated below:

January 10, 2002

Date of Signature  
and of Mail Deposit  
Karen DiRoccoAssistant Commissioner of Patents  
Washington, D.C. 20231**REPLY UNDER 37 CFR 1.116**

Sir:

This amendment is being filed in reply to the outstanding Office Action, mailed May 9, 2001, and the Advisory Action mailed December 17, 2001, in connection with the above application. Please enter the following amendments:

**In the claims:**

For the convenience of the Examiner, all claims being examined, whether or not amended, are presented below.

14. (Amended) A substantially pure nucleic acid comprising a nucleotide sequence which encodes a CAK1 polypeptide at least 75% identical to an amino acid sequence represented in SEQ ID No. 14.

15. The nucleic acid of claim 14, wherein the encoded CAK1 polypeptide functions in one of either role of an agonist or an antagonist of cell cycle regulation of a *Candida* cell.